Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered. Zhao B, Ma W. J Thorac Oncol 2022;17:e85-e86.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao B, Ma W. Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered. J Thorac Oncol 2022;17:e85-e86.
PMID: 36031298